Investigational Chimeric Antigen Receptor T-cell Therapy: Researching a New Path for Cancer Treatment

Investigational CAR T Therapy: Researching a New Path for Cancer Treatment

Caption

CTL019 targets a protein called CD19 and is the first investigational chimeric antigen receptor T-cell (CAR-T) therapy identified for development under the Penn-Novartis alliance.

Usage Rights & Restrictions

This media asset is free for editorial broadcast, print, online and radio use. It is restricted for other purposes.

Download (image 2.71 MB)